← Back to patent-cliff list
Albuterol sulfate/fluticasone propionate (Teva Branded Pharmaceutical Industries)
Tier C — Watch / tradeAlbuterol sulfate/fluticasone propionate (Teva Branded Pharmaceutical Industries)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Steroid hormone receptor, ADRB2, GR, PLA2G4A
Indications (approved)：Asthma
Regional status
US
Phase III
2024-12-12
EU
Phase III
2024-12-12
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Albuterol sulfate/fluticasone propionate (Teva Branded Pharmaceutical Industries)?
Approved indications include: Asthma.
When does the Albuterol sulfate/fluticasone propionate (Teva Branded Pharmaceutical Industries) patent expire?
No public expiry year is available for Albuterol sulfate/fluticasone propionate (Teva Branded Pharmaceutical Industries) yet; this page updates once verified.
How do I get a quote for Albuterol sulfate/fluticasone propionate (Teva Branded Pharmaceutical Industries) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03